Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Pharmacyte Biotech Inc (NQ: PMCB ) 1.810 -0.060 (-3.21%) Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Pharmacyte Biotech Inc < Previous 1 2 Next > PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease May 21, 2024 From PharmaCyte Biotech, Inc. Via Business Wire PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women’s Health Innovator Femasys, Inc. November 15, 2023 From PharmaCyte Biotech, Inc. Via Business Wire Femasys Inc. Secures Additional Financing with Strategic Investment from Investors led by PharmaCyte Biotech November 15, 2023 From Femasys Inc. Via GlobeNewswire PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology October 31, 2023 From PharmaCyte Biotech, Inc. Via Business Wire PharmaCyte Biotech Announces Final Results of Tender Offer June 15, 2023 From PharmaCyte Biotech, Inc. Via Business Wire PharmaCyte Biotech Announces Cash Tender Offer for up to 7,750,000 Shares at $3.25 Per Share May 11, 2023 From PharmaCyte Biotech, Inc. Via Business Wire PharmaCyte Biotech to Implement Second $10-Million Share Repurchase Plan February 02, 2023 From PharmaCyte Biotech, Inc. Via Business Wire PharmaCyte Biotech Reaches Cooperation Agreement with Iroquois Capital August 15, 2022 From PharmaCyte Biotech, Inc. Via Business Wire PharmaCyte Biotech Rebukes Iroquois’ Commencement of Consent Solicitation July 28, 2022 From PharmaCyte Biotech, Inc. Via Business Wire PharmaCyte Biotech Commences First Phase of Two-Phase Pig Study July 21, 2022 From PharmaCyte Biotech, Inc. Via Business Wire PharmaCyte Biotech Reports Positive Interim Results in Malignant Ascites Mouse Model Study July 19, 2022 From PharmaCyte Biotech, Inc. Via Business Wire PharmaCyte Biotech Announces Preliminary Unaudited Financial Results for Fiscal Year 2022 July 11, 2022 From PharmaCyte Biotech, Inc. Via Business Wire PharmaCyte Biotech Announces Additional Quality Control Assay and Confirms Stability of CypCap Cells July 05, 2022 From PharmaCyte Biotech, Inc. Via Business Wire PharmaCyte Biotech Issues Follow-Up Response to Iroquois Capital’s Second Letter on June 9 and Reiterates Commitment to Increasing Shareholder Value June 15, 2022 From PharmaCyte Biotech, Inc. Via Business Wire PharmaCyte Biotech to Attend 2022 BIO International Convention in San Diego June 13, 2022 From PharmaCyte Biotech, Inc. Via Business Wire PharmaCyte Biotech Issues Response to Iroquois Capital Letter and Announces Additional Steps to Increase Shareholder Value June 08, 2022 From PharmaCyte Biotech Via Business Wire PharmaCyte Biotech to Implement $10-Million Share Repurchase Program June 02, 2022 From PharmaCyte Biotech, Inc. Via Business Wire PharmaCyte Biotech Initiates Studies to Confirm Its Pancreatic Cancer Therapy Can Treat Malignant Ascites May 23, 2022 From PharmaCyte Biotech, Inc. Via Business Wire PharmaCyte Biotech to Attend 15th International Conference on Advanced Technologies and Treatments for Diabetes April 27, 2022 From PharmaCyte Biotech, Inc. Via Business Wire PharmaCyte Biotech Announces More Positive Tests Results for Its Pancreatic Cancer Clinical Trial Product Candidate to Satisfy FDA Requirements April 19, 2022 From PharmaCyte Biotech, Inc. Via Business Wire PharmaCyte Biotech to Accelerate Preparations for Start of Pancreatic Cancer Clinical Trial April 13, 2022 From PharmaCyte Biotech, Inc. Via Business Wire PharmaCyte Biotech Appoints Dr. Matthias Löhr to Board of Directors April 05, 2022 From PharmaCyte Biotech, Inc. Via Business Wire PharmaCyte Biotech Successfully Completes 24-Month Stability Study of Its Clinical Trial Product Candidate March 22, 2022 From PharmaCyte Biotech, Inc. Via Business Wire PharmaCyte Biotech Reports Third Quarter Financial Results and Operational Highlights March 16, 2022 From PharmaCyte Biotech, Inc. Via Business Wire PharmaCyte Biotech Announces Genetic Stability of Cytochrome P450 Gene and Site of Integration February 22, 2022 From PharmaCyte Biotech, Inc. Via Business Wire PharmaCyte Biotech Updates Status of Investigational New Drug Application to FDA February 14, 2022 From PharmaCyte Biotech, Inc. Via Business Wire PharmaCyte Biotech to Present at H.C. Wainwright BioConnect Conference January 06, 2022 From PharmaCyte Biotech, Inc. Via Business Wire PharmaCyte Biotech Study Proves Capsule Material Is Not Toxic For Encapsulated Cells January 04, 2022 From PharmaCyte Biotech, Inc. Via Business Wire PharmaCyte Biotech Successfully Completes 36 Month Master Cell Bank Stability Study December 28, 2021 From PharmaCyte Biotech, Inc. Via Business Wire PharmaCyte Biotech Reports Second Quarter 2021 Financial Results and Operational Highlights December 15, 2021 From PharmaCyte Biotech, Inc. Via Business Wire < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
